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Aim: Lactococcus lactis is a Gram-positive (endotoxin-free) food-grade bacteria 
exploited as alternative to Escherichia coli for recombinant protein production. We 
have explored here for the first time the ability of this platform as producer of complex, 
self-assembling protein materials. Materials & methods: Biophysical properties, cell 
penetrability and in vivo biodistribution upon systemic administration of tumor-
targeted protein nanoparticles produced in L. lactis have been compared with the 
equivalent material produced in E. coli. Results: Protein nanoparticles have been 
efficiently produced in L. lactis, showing the desired size, internalization properties 
and biodistribution. Conclusion: In vitro and in vivo data confirm the potential and 
robustness of the production platform, pointing out L. lactis as a fascinating cell factory 
for the biofabrication of protein materials intended for therapeutic applications.
First draft submitted: 15 May 2016; Accepted for publication: 20 July 2016; Published 
online: 17 August 2016
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Background
Protein materials benefit from their generic 
biocompatibility, full biodegradability and 
functional and structural convergence, which 
can be adjusted to particular purposes by 
genetic design. Also, proteins can be pro-
duced by biofabrication in cell factories by 
fully scalable, tuneable and cost-effective 
processes [1]. The optimization of methodolo-
gies for protein production has allowed the 
approval, by the major medicament agencies 
(namely US FDA and EMA), of hundreds of 
protein drugs for human use. In this context, 
the global market for recombinant protein 
and peptidic drugs has been growing since 
2007 at an annual rate of 10%, achiev-
ing US$160.1 billion and US$50.4 billion, 
respectively, in 2013 [2]. Interestingly, there 
is a manifest trend toward the generation of 
protein drugs whose amino acid sequences 
have been modified, versus the use of natural, 
unmodified protein versions [3]. In this direc-
tion, and as a side aspect of protein drug devel-
opment, many principles of protein engineer-
ing allow the production of self-assembling 
polypeptides as building blocks of complex 
oligomeric structures [4]. Protein self-assem-
bling results in both amorphous and defined 
morphometries that include fibers, layers, rib-
bons, cages, particles and hydrogels. Protein 
materials resulting from self-assembling of 
building blocks are generically biocompatible 
and highly tuneable, exhibiting diverse appli-
cations in biomedicine (for targeted drug 
delivery, local drug release, protein replace-
ment therapies and tissue engineering, among 
others) [5], what demand standardized and 
safe production methods.
Besides the ex vivo chemical synthesis of 
short peptides, recombinant protein produc-
tion comprises a rich set of procedures deeply 
explored for biotechnological and biopharma 
products. Many types of cell factories are 
under development to expand the versatil-
ity of biological production and to adjust the 
final quality of products to the increasing 
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regulatory demands [6]. In this context, the absence of 
endotoxins is required for in vivo uses because these 
molecules promote pyrogenicity and potent inflamma-
tory responses [7]. This fact makes strongly advisable 
the use of endotoxin-free cell factories [8–12]. In this 
context, the Gram-positive (endotoxin-free) group of 
lactic acid bacteria (LAB) represents a promising plat-
form for protein production as these species combine 
fast bacterial growth (vs eukaryotic platforms), easy 
culture with adjustable conditions and the food-grade 
denomination [13–15]. Among LAB, the genome of Lac-
tococcus lactis was the first sequenced and the genetic 
tools for gene cloning and expression already devel-
oped for this species are particularly efficient. The L. 
lactis toolbox particularly favors protein secretion and 
high solubility levels, and the use of this platform thus 
addresses another of the major bottlenecks in bacterial 
protein production, which is protein aggregation [16]. 
Many proteins with therapeutic interest have been 
already produced in a soluble and biologically active 
form, for instance cytokines [17–22], hormones [23] and 
antigens [24–29]. Interestingly, LAB and especially 
L. lactis also offer the potential of adaptation for use in 
form of living vector cells for in vivo delivery of immu-
nogens, therapeutic proteins and nucleic acids [30,31]. 
In these applications proteins are released from bac-
teria administered intranasal or orally, what largely 
expands the spectrum of therapeutic applications of 
this  particular production system [13,32–35].
Despite its potential for the production of thera-
peutic polypeptides, the performance of such still 
emerging production system has not been explored yet 
regarding the biological fabrication of building blocks 
of complex nanostructured protein materials. As fur-
ther protein assembling as functional supramolecular 
structures depends on protein conformation, and pro-
tein conformation is subjected to the performance of 
the cell’s quality control system, different bacterial spe-
cies might behave differently as cell factories regarding 
the final structure and functional quality of protein 
materials. To address this issue, we have produced in 
L. lactis CXCR4-targeted, smart protein nanopar-
ticles formed by the modular protein T22-GFP-H6, 
previously designed for production in Escherichia coli. 
Because of its full characterization and suitability for 
potent recombinant gene expression, the nisin-con-
trolled gene expression system was selected for protein 
production in this species [36]. Nanoparticles, as mate-
rials with regular geometry and a size below 100 nm, 
offer interesting advantages as drug carriers regarding 
distribution in organic tissues and enhanced cellular 
penetrability, especially regarding oncological treat-
ments [37]. Production of T22-GFP-H6 nanoparticles 
in L. lactis has been approached for a further charac-
terization and comparison of the properties of the same 
material produced in E. coli, at molecular, supramo-
lecular and also systemic level. The nanoparticles pro-
duced in L. lactis successfully accumulated in primary 
tumor and metastasis in CXCR4+ colorectal cancer 
mice models upon systemic administration, proving a 
specific targeting for tumoral cells that has been also 
confirmed in vitro by using CXCR4 ligands as bind-
ing inhibitors. While the data obtained here indicated 
robust targeting and biological behavior of the pro-
tein nanoparticles produced in L. lactis, confirming 
this system as a promising factory for complex pro-
tein materials, they also revealed detectable variabil-
ity in relevant structural and functional features when 
comparing materials handled by alternative bacterial 
 species with functionally different quality controls.
Methods
Strains, plasmid, culture & protein production 
conditions
Strains and plasmids used in this study and their most 
relevant features are listed in Table 1. Lactococcus lactis 
(NZ9000 strain) was transformed by electroporation 
with pNZ8150, while E. coli Origami B strain was 
transformed by heat shock with pET22b. Both plas-
mids encode, with optimized codon usage for every 
host (synthesized by GeneArt), the modular protein 
T22-GFP-H6, which when fabricated in E. coli (T22-
GFP-H6coli) self-assembles into regular toroid particles 
of about 14 nm. T22 is a cationic peptide that apart 
from promoting protein–protein contacts in nanopar-
ticles formed by T22-GFP-H6 as building blocks [38], it 
binds specifically to the cell surface cytokine CXCR4, 
overexpressed in colorectal cancer and correlating with 
aggressiveness and progression of the disease [39]. T22 
promotes internalization of the whole nanoparticle in 
CXCR4+ cells [40] and its intracellular accumulation in 
tumor and secondary metastatic foci in vivo [41]. Being 
colorectal cancer a central health problem and metas-
tasis the main cause or mortality in colorectal cancer, 
a protein nanoparticle targeted to metastatic CXCR4+ 
colorectal cancer cells represents a promising vehicle 
for targeted delivery of conventional and innovative 
antitumoral drugs. Lactococcus lactis was cultured in 
M17 media (Sigma) enriched with 0.5% glucose and 
E. coli in Lysogenic Broth media (Sigma). Overnight 
cultures were prepared from a bacterial glycerol stock 
to inoculate shake flasks containing 500 ml of the 
appropriate media and antibiotics. Lactococcus lactis 
was cultured at 30°C without shaking and E. coli at 
37°C and 250 rpm, growing up to 0.5 OD
550
 units. 
T22-GFP-H6 gene expression in L. lactis was induced 
by 12.5 ng/ml nisin and cultures were incubated over-
night at 30°C without shaking. In E. coli, gene expres-
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sion was induced by IPTG at 1 mM and cultures were 
incubated overnight at 20°C and 250 rpm.
Protein purification
Both species of bacterial cells were harvested by cen-
trifugation (5000 × g at 4°C, 15 min) and resuspended 
in wash buffer (20 mM Tris-HCl, 500 mM NaCl and 
10 mM imidazole), containing an EDTA-free prote-
ase inhibitor cocktail (Roche). Afterward, E. coli cells 
were disrupted by pressuring two rounds at 1200 psi 
(machine pressure) and L. lactis cells with three rounds 
at 1500 psi in a French press (Thermo FA-078A). Both 
T22-GFP-H6coli and T22-GFP-H6lactis proteins were 
purified by His-tag affinity chromatography using 
1 ml HiTrap Chelating HP column (GE Healthcare) 
through an ÄKTA pure FPLC (GE Healthcare). Sepa-
rations were made by linear gradient of elution buffer 
(20 mM Tris, 500 mM NaCl and 500 mM imidaz-
ole). Purified protein fractions were dialyzed against 
carbonate buffer (166 mM NaCO
3
H, pH 7.4). Pro-
tein amounts were determined by Bradford’s assay [42] 
and analyzed by conventional denaturing SDS-poly-
acrylamide gel electrophoresis (15% polyacrylamide), 
using a commercial polyclonal antibody against green 
fluorescent protein (GFP; Santa Cruz Biotechnol-
ogy). Protein purification was assisted by the ICTS 
‘NANBIOSIS,’ more specifically by the CIBER-BBN’s 
 Protein Production Platform [43].
Electron microscopy
T22-GFP-H6 nanoparticles were examined by trans-
mission electron microscopy (TEM) and field emission 
scanning electron microscopy (FESEM). For TEM, 
protein samples were negatively stained with uranyl 
acetate by conventional methods [41] and observed in a 
Jeol 1400 microscope operating at 80 kV and equipped 
with a CCD Gatan Erlangshen ES1000W camera. For 
FESEM, protein samples were directly deposited over 
silicon wafers, air dried and observed with an in-lens 
secondary electron detector through a Zeiss Merlin 
microscope operating at 2 kV.
Determination of particle size & fluorescence
Particle size was measured by two different techniques. 
By dynamic light scattering (DLS, Zetasizer Nano ZS, 
Malvern), volume size distribution was determined 
at 633 nm. Using FESEM micrographs, diameters of 
nanoparticles were measured by ImageJ software (NIH, 
MD, USA). GFP fluorescence emission (510 nm) was 
determined on purified proteins with a Cary Eclipse 
fluorescence spectrophotometer (Agilent Technologies) 
using an excitation wavelength of 450 nm.
Cell culture, flow cytometry & confocal 
microscopy
Protein internalization was analyzed in CXCR4+ HeLa 
cell cultures in 24-well plates. Briefly, the Minimum 
Essential Medium medium supplemented with 10% 
FBS and 2 mM Glutamax (Gibco) was removed and 
cells were washed in PBS. Then 250 μl of 500 nM 
T22-GFP-H6 protein, diluted in OptiPro medium 
supplemented with L-Glutamine, were added and 
incubated for 2 h, at 37°C at 5% CO
2
 to allow cell 
binding and internalization. Then, harsh trypsin diges-
tion (1 mg/ml for 15 min) was carried out to remove 
protein particles bound to the outer size of the cell 
membranes [44]. Intracellular green fluorescence was 
analyzed by flow cytometry on an FACS-Canto system 
(Becton Dickinson) using a 15 mW air-cooled argon 
ion laser at 488 nm excitation. Fluorescence emission 
was measured with a D detector (530/30 nm band pass 
filter), and manually corrected by the specific fluores-
cence of purified protein, to get data representative of 
the amount of internalized protein for comparative 
purposes. For competition assays, a specific CXCR4 
inhibitor AMD3100 (octahydrochloride hydrate, 
Sigma Aldrich) was added 1 h before T22-GFP-H6 
nanoparticles addition in a 1:10 (protein: AMD3100) 
molar ratio. For confocal analysis, cells were grown to 
100,000 cells/ml on MatTek culture dishes (MatTek 
Corporation) for 24 h at 37°C at 5% CO
2
. Then, 500 
nM T22-GFP-H6 in 1 ml OptiPro medium supple-
mented with L-Glutamine was added, and incubated 
for 24 h at 37°C and 5% CO
2
. Before confocal obser-
vation, nuclei were labeled with 5 μg/ml Hoechst 
33342 (Life Technologies) and plasma membranes 
with 2.5 μg/ml CellMaskTM Deep Red (Life Technolo-
gies) for 10 min in the dark. Micrographs were then 
taken by TCS-SP5 confocal laser scanning micros-
copy (Leica Microsystems) using a Plan Apo 63×/1.4 
Table 1. Strains and plasmids used in this study.
Bacterial strains and plasmids Relevant genotype or phenotype Ref.
Lactococcus lactis subsp. cremoris NZ9000 pepN::nisRnisK [20]
Escherichia coli Origami B OmpT-, Lon-, TrxB-, Gor-, StrepR, TetR [21]
pNZ8150-T22-GFP-H6 CmR(5 μg/ml), nisin-inducible This work
pET22b-T22-GFP-H6 ApR(100 μg/ml), IPTG-inducible [22]
10.2217/nnm-2016-0200 Nanomedicine (Lond.) (Epub ahead of print) future science group
Preliminary Communication    Cano-Garrido, Céspedes, Unzueta et al.
(oil HC × PL APO lambda blue) objective. In order to 
localize T22-GFP-H6 nanoparticles inside cells, stacks 
of 40–60 sections for every 0.25 μm of cell thickness 
were collected and 3D models were generated using 
Imaris software (Bitplane).
Biodistribution of T22-GFP-H6 variants in 
CXCR4+ colorectal cancer mouse models
Five-week-old female swiss nude mice, weighing 
18–20 g (Charles River) and maintained in specific 
pathogen-free conditions were used for the in vivo 
experiments. They were performed by the ICTS ‘NAN-
BIOSIS’, more specifically by the CIBER-BBN’s Nano-
toxicology platform of IIB Sant Pau [45], and all proce-
dures were approved by the Hospital de Sant Pau ethical 
committee in accordance with Institutional guidelines.
To generate the subcutaneous (sc.) CXCR4+ CRC 
model, aliquots of 10 mg of SP5 CXCR4+ tumor tissue 
from donor animals were obtained and implanted sc. 
of mice by the trocher system. When tumors reached 
500 mm3 approximately, mice were randomly allocated 
and biodistribution was performed. T22-GFP-H6 
nanoparticles in carbonate buffer (166 mM NaCO
3
H, 
pH 7.4) were administered intravenously at 500 μg/
mouse (n = 3). The control mice received empty buf-
fer (n = 3). Five hours postadministration, mice were 
euthanized by cervical dislocation and tumors and 
organs were extracted for ex vivo recording and quan-
tifying the fluorescence emitted by each organ. GFP 
fluorescence signals were detected using the IVIS spec-
trum equipment (Perkin Elmer). The fluorescence 
signal was first digitalized, displayed as a pseudocolor 
overlay and expressed as radiant efficiency ([p/s/cm2/
sr]μW/cm2). Data were corrected by the specific fluo-
rescence of purified protein, to get data representative 
of the amount of internalized protein, for comparative 
purposes. Finally, tumors and all organs were collected 
and fixed with 4% formaldehyde in phosphate- buffered 
solution for 24 h, and then embedded in paraffin for 
 immunohistochemical evaluation.
Histology & immunohistochemistry
Four-micrometer-thick sections were stained with 
hematoxylin and eosin, and a complete histopatho-
logical analysis was performed by two independent 
observers. Immunohistochemistry (IHC) stains were 
performed on a DAKO Autostainer automated Link48 
(DAKO) using standard procedures. The anti-GFP 
antibody (1:100, Santa Cruz Biotechnology) was used 
to detect nanoparticle accumulation and localiza-
tion in tumors and normal tissue as described previ-
ously [41]. Representative images were taken using 
Cell∘B software (Olympus Soft Imaging) at 200× and 
400× magnifications.
Results
The modular protein T22-GFP-H6 (Figure 1A), dis-
playing the peptidic CXCR4 ligand T22, was pro-
duced in L. lactis and purified in a single peak from 
bacterial cell extracts. T22-GFP-H6lactis resulted in 
a polypeptide of the expected molecular mass (30.6 
KDa), suffering only from mild proteolytic degrada-
tion (Figure 1B & C). The protein material occurred 
in form of nanoparticles that in dynamic light scat-
tering peaked at 20.9 nm, showing also a polydis-
perse secondary population of around 100 nm that 
might correspond to soluble aggregates. Under micro-
scopic examination, regular toroid nanoparticles were 
observed, similar in morphology to those formed by 
the same protein when produced in E. coli Origami B 
but of larger size (20 vs 14 nm).
Regarding functionality, those particles emitted flu-
orescent light (as expected, because of the presence of 
GFP), and their specific fluorescence was determined 
to be 3.12-fold lower than the value obtained for T22-
GFP-H6coli nanoparticles produced in Origami B 
under comparable production conditions (Figure 2A). 
Their intrinsic fluorescence was used as reporter to 
check the ability of the material to penetrate CXCR4+ 
cells in a receptor-dependent way, what was compara-
tively done regarding the protein source. While the 
uptake of both nanoparticle versions was efficiently 
inhibited by AMD3100 (86.7% in the case of E. coli 
materials and 96.6% in the case of the food-grade 
nanoparticles), proving the specificity in cell entry in 
both cases, penetration of the material produced in L. 
lactis was surprisingly higher than that produced in E. 
coli (Figure 2A). In previous uptake analyses of GFP-
based nanoparticles produced in diverse E. coli strains 
we observed a negative correlation between the capac-
ity to internalize cells and the specific fluorescence of 
the material, indicative of alternative arrangements of 
the oligomers, affecting both the performance of the 
fluorophore and that of the cell active peptides (namely 
T22 and H6, as ligand and endosomal escape agents, 
respectively). Interestingly, T22-GFP-H6lactis materials 
perfectly fit in this model (red dots, Figure 2B).
The efficient and highly specific CXCR4 target-
ing, good penetration (Figure 2A) and the intracellular 
accumulation of the nanoparticles that remained fully 
fluorescent (Figure 2C & D), prompted us to evaluate 
the performance of the material in vivo, regarding 
biodistribution in CXCR4+ colorectal cancer mice 
models upon systemic administration. In animals 
treated with either material (Figure 3A), fluorescence 
largely accumulated in primary tumor as expected 
(Figure 3B & E), with only background signal in non-
target organs (Figure 3C) that might be due to tis-
sue self-fluorescence within the GFP emission range. 
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Figure 1. Nanoscale characterization of T22-GFP-H6lactis nanoparticles (continued overleaf). (A) Modular scheme of T22-GFP-H6. 
Relative lengths of the modules are only approximate. (B) Fractions from 7 to 13 resulting from one-step protein purification of T22-
GFP-H6lactis in His-tag affinity chromatography that were pooled for further studies. (C) Mass spectrometry analysis of T22-GFP-H6lactis. 
(D) Volume size distribution of nanoparticles determined by DLS.
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Figure 1. Nanoscale characterization of T22-GFP-H6lactis nanoparticles (cont.). (E) Representative micrographs of a detail of T22-GFP-
H6lactis nanoparticles obtained by TEM (up) and by FESEM (down). (F) FESEM micrograph showing a general field of T22-GFP-H6lactis 
nanoparticles. (G) FESEM micrograph showing a general field of T22-GFP-H6coli nanoparticles. Bars indicate 20 nm. 
DLS: Dynamic light scattering; FESEM: Field emission scanning electron microscopy; TEM: Transmission electron microscopy.
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While selective tumor targeting was excellent in the 
case of T22-GFP-H6coli nanoparticles, those produced 
in L. lactis showed moderate but detectable accumu-
lation in liver that was presumed when analyzing the 
whole organ but that was confirmed in liver sections 
(Figure 3C & F). Quantitative analysis of the signal, 
upon correction by the specific fluorescence of the 
variant nanoparticles confirmed a similar biodistribu-
tion pattern of both materials as well as the enhanced 
deposition in liver of T22-GFP-H6lactis (Figure 3D). 
This might be primarily due to the slightly enhanced 
particle size comparing with the material produced in 
E. coli or to an expansion of the conformational spec-
trum of protein nanoparticles when produced in the 
Gram-positive cell factory.
Discussion
Among the diversity of cell factories for protein drug 
production [6], bacteria offer greater opportunities for 
cost-effective production at industrial scale and higher 
process versatility. Being E. coli the choice produc-
tion system [14,47], endotoxin contamination of bac-
terial products is a major issue of concern [48]. Given 
the increasing trend in the approval of protein-based 
drugs [3] and in the line of the convenient biological 
fabrication of nanostructured protein materials [1], the 
production of endotoxin-free protein for biomedical 
uses is gaining relevance. While industrial-scale pro-
tocols for endotoxin removal have been implemented 
and largely tested for conventional-soluble recombi-
nant proteins [8,11–12,48], attention has not been paid yet 
to self-assembling protein materials exhibiting a higher 
structural complexity and more prompt to retain 
undesired contaminants. In this context, endotoxin-
free E. coli strains have been recently developed [10] 
and proved to be appropriate for the successful pro-
duction of soluble protein drugs [10] as well as of more 
complex protein materials such as inclusion bodies [49] 
and tumor-targeted protein nanoparticles [50]. Interest-
ingly, both the architecture and functionalities of smart 
protein materials intended for in vivo administration, 
such as LDLR-, CXCR4- or CD44-targeted nanopar-
ticles [41,51–52], are significantly influenced by the per-
formance of the quality control of the producing E. coli 
cells [46,53]. In turn, the quality control network might 
be, itself, modulated by the particular genetics that is 
necessary to reach the endotoxin-free status [46].
The food-grade lactic acid bacterium L. lactis has 
emerged as a promising protein production plat-
form [16,54–55], naturally devoid of endotoxins and suit-
able for oral and intranasal administration as a living 
drug (DNA and protein) delivery system [30,35,56–59]. 
This microorganism has been mainly employed for 
the secretion of difficult-to-express proteins in soluble 
forms [16,60] and for the preparation of S-layers for 
ordered protein display purposes [61]. Although it has 
been also used for the controlled preparation of nano-
structured biopolyester beads [62] and hybrid poly-
hydroxybutyrate–protein granules [63] among a few 
other materials, L. lactis has been never explored regard-
ing the quality and activities of complex self-assembling 
protein materials. It is anticipated that the L. lactis qual-
ity control might act differently than that of E. coli, 
because of the occurrence of different regulators of stress 
responses [64], by the potentially divergent activities of 
the main cytosolic chaperone DnaK [64] and by alterna-
tive ways in which these species appear to manage pro-
tein aggregation [54,65]. Therefore, we were interested in 
knowing if L. lactis might be supportive of proper pro-
duction of cell-targeted protein nanoparticles usable as 
in vivo drug vehicles for intracellular drug delivery [66]. 
The data obtained in the present study fully confirm 
the robustness of the self-assembling protein platform, 
since the expected toroid T22-GFP-H6 nanoparticles 
are produced in L. lactis (Figure 1E & F) specifically bind 
the CXCR4 cytokine receptor (Figure 2A) and effi-
ciently internalize CXCR4+ cells (Figure 2C & D), in a 
pathway compatible with endosome-mediated uptake. 
However, the slight but consistent size difference 
observed between T22-GFP-H6lactis and T22-GFP-
H6coli (Figure 1), and the lowest specific fluorescence 
but higher penetrability of T22-GFP-H6lactis (Figure 2) 
confirm that T22-GFP-H6 building blocks are distinc-
tively organized in these bacterial cell factories. When 
analysing data from T22-GFP-H6 variants produced 
in several E. coli strains, we previously found a nega-
tive relationship between fluorescence emission and cell 
penetrability of the resulting nanoparticles [46]. Since 
T22-GFP-H6lactis fits in this T22-GFP-H6coli model 
(Figure 2B) indicates that the impact of protein confor-
mation (or the oligomeric organization) on the mate-
rial performance is irrespective of the given protein 
 production platform used for biofabrication.
Furthermore, T22-GFP-H6lactis efficiently accumu-
lates in tumor upon systemic administration (Figure 3), 
escaping from renal clearance and proving the stability 
of the material and the good performance in vivo of 
the tumor homing peptide T22, as folded in L. lac-
10.2217/nnm-2016-0200www.futuremedicine.com
Figure 2. Cell penetrability of T22-GFP-H6lactis nanoparticles into CXCR4+ HeLa cells. (A) Protein amounts 
internalized into cells depending on the cell factory used for production, and uptake inhibition promoted by the 
natural CXCR4 ligand AMD3100 (AMD). Intracellular fluorescence was corrected by specific fluorescence to render 
values representative of protein amounts. Asterisk indicates significant differences (p ≤ 0.05). (B) Internalization 
efficiently represented versus specific fluorescence (as raw data, top and as logarithm, bottom) of T22-GFP-
H6lactis nanoparticles produced in L. lactis (red dots) compared with the same materials produced in several E. 
coli strains, as previously reported [46]. (C) Confocal images of HeLa cells exposed to 500 nM of L. lactis T22-GFP-
H6lactis nanoparticles for 24 h. Cell membranes are labeled in red and nuclei in blue. Green signals correspond 
to fluorescent nanoparticles. In the inset, a 3D Imaris reconstruction shows the accumulation of the material 
in the cell cytoplasm. This precise intracellular localization is confirmed by a fluorescence intensity profile of a 
representative cell exposed to nanoparticles. (D) The high penetrability of the material from L. lactis combined 
with its low fluorescence emission fitted very precisely in the model we had formerly generated to explain such 
inverse relationship (Figure 2B), supporting the concept that penetrability is linked to the precise oligomeric 
architecture of the materials that can impact, in its own, via conformation, on the fluorophore performance. 
T22-GFP-H6lactis nanoparticles accumulated in the cytoplasm of target cells in absence of any detectable toxicity 
(Figure 2C & D).
0
500
1000
1500
2000
R
el
at
iv
e 

u
o
re
sc
en
ce
E. coli
*
*
E. coli + AMD L. lactis L. lactis + AMD
2500
0
100
200
300
400
E
G
F
4000 80000 12,000 16,000
500
0
1
2
3
4
In
(E
G
F
)
7
5
6
Aesp
Aesp
4000 80000 12,000 16,000
0
200
In
te
n
si
ty
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
250
240
230
220
210
(μm)
4 62 8 10 14 16 2012 18
future science group
CXCR4+-targeted protein NPs produced in the food-grade bacterium L. lactis    Preliminary Communication
tis. However, at difference from T22-GFP-H6coli that 
was only observed in tumor and metastasis, T22-GFP-
H6lactis is also found, at minor extend, in liver (but 
not in other nontarget organs). Although this fact is 
of course undesired, the accumulation in tumor of 
T22-GFP-H6lactis is more than two-fold than in the 
liver. In clinical oncology, approved and currently 
administered drugs such as antibody drug conjugates 
(e.g., trastuzumab emtansine), majorly accumulate in 
liver (80%), while only 1% of the injected dose reaches 
the tumor [67].
In this regard, the variant biodistribution map does 
not preclude the potential use of T22-GFP-H6lactis as 
vehicle for drug delivery in colorectal cancer, but it indi-
10.2217/nnm-2016-0200 Nanomedicine (Lond.) (Epub ahead of print)
Figure 3. Comparative biodistribution of T22-GFP-H6 nanoparticles in a CXCR4+colorectal cancer mouse model. (A) Representative 
fluorescence (arbitrary units) recording images and quantitation of specific GFP emission signal of each nanoparticle at the same 
concentration by the IVIS® spectrum system. (B) Ex vivo tumor fluorescence imaging (FLI) at 5 h postadministration of 500 μg/mouse 
dose of each T22-GFP-H6 variants (nanoparticles produced in either E. coli or L. lactis). Note the enhanced green fluorescence 
associated with nanoparticle accumulation in tumors produced in E. coli as compared with L. lactis nanoparticles. BF is empty buffer. 
(C) Ex vivo determination of GFP fluorescence signal in relevant organs such lung, brain, kidney and liver. No fluorescence was 
observed in any organ except for the liver of mice administered with T22-GFP-H6lactis. (D) Quantitation of ex vivo fluorescence emission 
(arbitrary units) in sectioned tumors and organs and expressed in radiant efficiency. Crude fluorescence values were corrected by 
the specific emission of each protein for comparative purposes. (E) Anti-GFP immunostaining showing membrane and cytosolic 
localization of T22-GFP-H6 variants in tumors which was absent in control animals injected with buffer (400× magnifications). (F) The 
presence and location of the T22-GFP-H6 lactic variant in liver tissue sections were demonstrated by anti-GFP immunohistochemistry 
(400× magnification). 
GFP: Green fluorescent protein.
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cates a peculiar oligomerization of the building blocks 
that influences targeting or promote passive accumula-
tion, though conferring particular biomechanical prop-
erties. Interestingly, T22-GFP-H6coli produced in an E. 
coli strain lacking DnaK chaperone, which have a key 
role in the E. coli quality control system, also show an 
aberrant distribution pattern, with a slight and unex-
pected accumulation in brain. In this context, the com-
parison of the stress responses of L. lactis and E. coli has 
prompted researchers suggesting different roles of chap-
erones among these species [64], and in fact, the quality 
controls of these two bacterial species show remarkable 
differences [68]. Then, the distinguishable biodistribu-
tion of the material observed here depending of the bac-
terial source suggests again a critical role of the protein 
quality control in defining the final fate of T22-GFP-
10.2217/nnm-2016-0200www.futuremedicine.comfuture science group
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H6 nanoparticles upon systemic administration. This 
might be due to a different conformational spectrum 
of nanoparticle variants depending on the quality con-
trol network of the used cell factory, which can slightly 
influence the availability of T22 for cross-molecular 
contacts or some subtle architectonic properties of 
nanoparticles that might result in morphometric modi-
fications leading to secondary accumulation in non-tar-
get organs such as liver. Irrespective of this fact, the bio-
logical fabrication of tumor-homing or other materials 
with biomedical properties in the food-grade bacterium 
L. lactis opens exciting opportunities for the delivery of 
these materials upon purification, as isolated protein 
preparations, or alternatively, through the administra-
tion of producing living cells by oral or intranasal routes 
already explored for this particular microbial cell fac-
tory and showing very promising potentialities in clini-
cal trials [69]. This last approach, to be yet tested with 
cell-targeted protein constructs, would allow the more 
effective treatment of conditions such as inflammatory 
conditions of the digestive system in which sustained 
mucosal delivery is particularly appropriate.
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Executive summary
•	 Lactococcus lactis, a food-grade lactic acid bacteria specifically exploited for the biofabrication of soluble 
protein species has been revealed here as a good producer of complex, self-assembling protein nanoparticles.
•	 Despite the robustness of the biological platform, the nanoscale architecture and biodistribution in colorectal 
cancer mice models reveals significant differences when compared with materials produced in E. coli. This fact 
supports a mechanistic impact of the protein quality control network on the systems level performance of the 
resulting product, which it is of critical relevance for the design of emerging, protein-only, nanostructured 
materials in biomedicine.
•	 Opening an exciting way for the production of high-quality, biologically safe protein nanoparticles with 
therapeutic interest, the present findings emphasize the suitability of L. lactis as a key player among the 
demanded, value-added cell factories for smart biomaterials.
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